• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Results of the PHOENIX Trial: Delivery or Expectant Management for Late Preterm Preeclampsia?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Guidelines advise delivery at 37w0d (or at time of diagnosis if later) for preeclampsia without severe features 
  • Chappell et al. (The Lancet, 2019) compared planned delivery vs expectant management (usual care) for late preterm (between 34 and 37 weeks) pre-eclampsia

METHODS:

  • Parallel-group, non-masked, multicenter, randomized controlled trial
  • Participants
    • 34w0d to 36w6d
    • Singleton or dichorionic diamniotic twin pregnancy
    • Diagnosis of preeclampsia or superimposed preeclampsia (per ISSHP guidelines)
  • Exclusion: Plan to deliver based on current practice of immediate delivery for preeclampsia with severe features
  • Groups (randomized)
    • Planned delivery (within 48 hours)
    • Expectant management (usual care)

Note: Algorithm used to balance certain features between groups such as study site, severity of BP, parity, previous cesarean and gestational age by week

  • Data analysis
    • Intention to treat
    • Sample size 450 per group (assuming loss to follow-up): Calculated using a 25% risk reduction | 5% significance level | 90% power
  • Primary outcome
    • Maternal: Composite of maternal morbidity or recorded systolic blood pressure of at least 160 mm Hg (superiority)
    • Perinatal: Composite of perinatal deaths or NICU admission up to infant hospital discharge (non-inferiority hypothesis)
  • Secondary outcomes: Individual components of composite outcomes such as use of anti-hypertensives, progression to severe preeclmapisa etc.

RESULTS:

  • 450 women planned delivery group | 451 women were in the expectant management group
  • Planned delivery group
    • Only 2 women had spontaneous onset of labor
    • 73% initiated within 48 hours
  • Expectant management
    • 54% had medically indicated delivery <37 weeks
    • Only 2 women delivered <37 weeks without a medical indication
  • The incidence of the co-primary maternal outcome was significantly lower in the planned delivery group (mothers)
    • Planned delivery group: 65%
    • Expectant management group: 75%
    • Adjusted relative risk (RR) 0.86 (95% CI 0.79 to 0.94; p=0.0005)
  • The incidence of the co-primary perinatal outcome was significantly higher in the planned delivery group (infants)
    • Planned delivery group: 42%
    • Expectant management group: 34%
    • Adjusted RR 1.26 (95% CI, 1.08 to 1.47; p=0.0034)
  • Secondary outcomes
    • Adverse maternal component outcomes were also significantly lower in the planned delivery group (e.g, SBP ≥160 mm Hg, progession to severe preeclampsia)
    • Adverse perinatal component outcome was significantly higher in the planned delivery group specifically for NICU admission due to prematurity but no differences in need of oxygen, length of stay, RDS, hypoglycemia, jaundice, infection or SGA  
    • Spontaneous vaginal delivery significantly higher in expectant group (36%) vs planned delivery group (29%); RR 1.21| 95% CI, 1.04 to 1.41)
    • Gestational age at delivery was earlier by 5 days in the planned delivery group (252 days) vs the expectant management group (257 days)

CONCLUSION:

  • Planned delivery for late preterm preeclampsia resulted in reduced maternal morbidity and severe hypertension vs expectant management
  • NICU admissions were higher in the planned delivery group, but not associated with severe neonatal morbidities
  • The authors suggest that risk and benefits should be discussed with patients and further state that 

In conclusion, our trial supports offering initiation of delivery in women with late preterm pre-eclampsia

Learn More – Primary Sources:

Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

ACOG SMFM Recommendations: When to Deliver Medically Complicated Pregnancies
Diagnosing Preeclampsia – Key Definitions and ACOG Guidelines
Deliver Low Risk Patients at 39 Weeks to Prevent Hypertensive Complications?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site